News

2022

Knopp Biosciences Presents New Phase 2 Data at AAAAI 2022 demonstrating that oral dexpramipexole improves airflow obstruction as measured by forced expiry volume (FEV1), largely through its effect on forced vital capacity (FVC)

2021

Phase 2 Trial Evaluating the Effect of Dexpramipexole on Eosinophil Biomarkers and Lung Function in Asthma

Oral Dexpramipexole Efficacy in Lowering Blood Eosinophils in Patients with Moderate to Severe Uncontrolled Eosinophilic Asthma

2019

Dexpramipexole Responsiveness is Increased in Eosinophilic Subjects

Developing Dexpramipexole for the Treatment of Eosinophilic Disorders

We use only necessary cookies to ensure our website can work correctly and to enhance your experience. For more information about the cookies we use, please see our Cookie Policy.